

Ankylosing Spondylitis Treatment Guidance for Biologic Drugs

INITIATING a Biologic requires

- Severe active disease
 - BASDAI \geq 4
 - **AND** VAS \geq 4cm
- **AND** Intolerance or lack of response to NSAIDs
- The most cost effective drug must be used first

Funding

Must be applied for via Blueteq for all Shropshire or T+W patients

- Initial funding is for a 12 week initiation period and 16 week initiation period for seckinumab.
- Continuation funding provides continuous approval until the drug is ineffective / not tolerated

CONTINUATION of a Biologic beyond 12 weeks requires (16 weeks for seckinumab only)

- A reduction in BASDAI \geq 50%
- **AND** a reduction spinal pain VAS score \geq 2cm

Sequencing

- **1st line** - Adalimumab biosimilar
- **2nd line** – Secukinumab or Etanercept
- **3rd line+** – Alternative licenced treatment

| Target | Drug | Included in NICE guidance | Comments / Conditions |
|--------------|--------------|---------------------------|-----------------------|
| TNF α | Adalimumab | TA383 | |
| | Etanercept | TA383 | |
| | Certolizumab | TA383 | |
| | Golimumab | TA383 | |
| IL 17 | Secukinumab | TA407 | |